Yoo Jeong-seon (EToday), 2020-09-22: Interview in which Kim Chul-min reports that after about five months on fenbendazole his liver enzymes rose and his metastases grew, that his tumour marker reached 1,650, and that he had stopped the drug and would not recommend it.
(복용 초기에는) 식욕도 좋아지고 목소리도 좋아지고 간 수치도 정상으로 돌아왔다"라며 "하지만 이게 한 5개월 정도 되니 다시 간 수치가 조금씩 오르고 암 전이됐던 데가 조금씩 더 크게 나타났다
Article body (unpaginated)
Yoo Jeong-seon (EToday), 2020-09-22: Interview in which Kim Chul-min reports that after about five months on fenbendazole his liver enzymes rose and his metastases grew, that his tumour marker reached 1,650, and that he had stopped the drug and would not recommend it. Patient-reported, not independently verified. Excerpt is the Korean original; English translation: '(Early on) my appetite improved, my voice improved and my liver counts went back to normal, but after about five months the liver counts started to rise again and the places the cancer had spread to began to grow.' Also reported: '절대 암을 죽이지 못했다' (it definitely did not kill the cancer); tumour marker rose to 1,650 from a previous peak of about 570-580; cervical spine (C5) lesion grew and new metastases appeared. Interview was with CBS radio 'Kim Hyun-jung's News Show' on 22 September 2020, published 2020-09-22 16:10. Drugs: fenbendazole taken from September 2019 for about a year, alongside Tagrisso (osimertinib) and radiotherapy. Outcome measured by liver function tests, imaging and tumour markers as reported by the patient and his doctors. Subject: Kim Chul-min, stage IV lung cancer diagnosed August 2019. Dose of fenbendazole not stated. Study type: news.
